Abstract:Objective: To evaluate the effect of paclitaxel and cisplatin (TP regimen) combined with intraperitoneal hyperthermic perfusion chemotherapy on immune function and quality of life in patients with advanced ovarian cancer. Methods: This retrospective study involved 107 patients with advanced ovarian cancer who were treated in Baoji Central Hospital between March 2016 and March 2020. The control group was treated with the TP regimen alone (n=48), while the observation group received additional intraperitoneal heat infusion chemotherapy containing 60 mg of cisplatin on the 8th day following the final chemotherapy (n=59). Immunoglobulin (IgG, IgA, IgM) levels, quality of life, tumor marker levels, incidence of adverse effects, and 3-year survival were compared between the two groups. Besides, factors affecting patients' prognosis were detected by unifactorial and multifactorial analyses. Results: Before treatment, there was no significant difference between the two groups in terms of IgG, IgA, and IgM levels (all P>0.05). After treatment, the observation group showed significantly higher levels of IgG, IgA, and IgM than those in the control group (all P<0.05). There were no significant differences in pre-treatment Kamofsky (KPS) score, carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125) between the two groups (all P>0.05). However, after treatment, the KPS score was significantly increased in the observation group as compared to pre-treatment or control group (both P<0.05), while CEA and CA125 significantly decreased in the observation group as compared to pre-treatment or control group (all P<0.05). Nevertheless, the incidence of gastrointestinal reactions in the observation group was higher than that in the control group (P<0.05). The survival rate of the observation group was significantly higher than that of the control group (P<0.05). The AUC of post-treatment IgG for predicting 3-year survival of patients was 0.743. The 3-year survival rate of patients with IgG≥10.950 g/L was significantly higher than that of patients with IgG<10.950 g/L (P<0.05). Multifactorial Cox regression analysis revealed that higher FIGO stage, presence of ascites, higher post-treatment IgG level, and higher post-treatment CEA and CA125 levels were independent risk factors for patients' 3-year mortality. Conclusion: TP regimen combined with intraperitoneal hyperthermic perfusion chemotherapy significantly improves immune function and quality of life in patients with advanced ovarian cancer, although it increases the incidence of gastrointestinal reactions. Higher FIGO stage, presence of ascites, higher IgG after treatment, higher CEA, and higher CA125 were independent risk factors for patients' 3-year mortality.

Effect observation on treating ovarian cancer with curcuma oil injection plus conventional chemotherapy

Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

Clinical study on advanced ovarian cancer by chemotherapy combined with radiotherapy

The Clinical Observation of the Patients with Medium-Term or Advanced Non-Small Cell Lung Cancer Treated with Brucea Javanica Oil Injection Combined with Chemotherapy

Anti-proliferation effect of paclitaxel with the combination of curcumin on human ovarian carcinoma cell line OC3

Inhibitory Effect of Curcumin-loaded Solid Lipid Nanoparticles Alone or Combined with DDP on the Growth of Human Ovarian Cancer Cell Line SKOV3

Inhibitory Effect of Curcumin-loaded Solid Lipid Nanoparticles Combined with Paclitaxel on Human Ovarian Cell Line HO-8910

The effect observation of chemotherapy with United Aidi injection in the treatment of advanced colorectal cancer

Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers

Effects of Traditional Chinese Medicine Anticancer Decoction Combined with Basic Chemotherapy and Nursing Intervention on Oral Cancer Patients after Surgery and Its Effect on Tumor Markers and Immune Function

Observation on Efficacy of Tegafur Gimeracil Oteracil Potassium Capsules Combined with Oxaliplatin in Treatment of Advanced Gastric CancerΔ

Clinical Observation of Early Postoperative Chemotherapy Combined with Traditional Chinese Medicine Adjuvant Therapy for Gastric Carcinoma

The Clinical Efficacy of Chemotherapy Combined with Traditional Chinese Medicine in the Treatment of Cervical Cancer and Its Influence on Cellular Immunity, Serum CEA, and TNF-α

Efficacy observation of primary chemotherapy combined with postoperative intraperitoneal hyperthermic perfusion chemotherapy for treatment of advanced ovarian cancer

Effects of TP regimen combined with intraperitoneal hyperthermic perfusion chemotherapy on immune function, quality of life and prognosis of patients with advanced ovarian cancer

Clinical Effects of Chinese Herbal Decoction Combined with Basic Chemoradiotherapy and Nursing Intervention in the Treatment of Cervical Cancer and the Effect on Serum CEA, CA125, and TNF-α Levels

Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125

Clinical study of shenqi fuzheng injection decreasing side-effects of tp chemotherapy for patients with gynecological malignant tumor